Delivery Order SPE2DB20D2002-SPE2DB26FK99A
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA Pen 40mg/4mL (2 pens) with a ceiling value of $26,615.29. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. HUMIRA...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used biologic immunosuppressant medication indicated for...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HUMIRA Pen 40mg/4ml in a quantity of two units. This firm fixed-price delivery order, valued at $22,915.94, represents a competitive award with no set-aside designation and is scheduled for completion by September 9, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab)...
- The Defense Logistics Agency awarded a delivery order valued at $3,776.50 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on July 9, 2025, with completion scheduled for July 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used immunosuppressant biologic medication prescribed for inflammatory conditions...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,895.53. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The delivery order is scheduled for completion by October 16, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a widely-used immunosuppressant medication for autoimmune conditions. This firm fixed-price delivery order, valued at $5,698.58, represents a competitive award with no set-aside designation and is scheduled for completion by August 22, 2025. The award was fulfilled from AmerisourceBergen's place of performance in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL pen injections, valued at $46,099.45. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of June 23, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL with a ceiling value of $12,769.53. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is classified as a child order, meaning it falls under a larger indefinite delivery vehicle. Performance is scheduled for completion by August 18, 2025, with...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL doses. This is a firm fixed price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. HUMIRA is a widely...
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB26FK99ADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL with a ceiling value of $1,132.95. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set to be completed by October 24, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used immunosuppressive medication used to treat various inflammatory and autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a critical prime vendor contract enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare systems and other federal healthcare agencies, including the Defense Health Agency and U.S. Coast Guard. As a major pharmaceutical distributor with substantial federal contract experience, AmerisourceBergen Drug Corp plays a significant role in ensuring pharmaceutical supply chain support for military personnel and federal beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 10/23/25 |